GrantMetric / States / Ohio / Cancer Research Grants

← Ohio Grants

🔬 OH STATE FEED

Cancer Research Grants in Ohio 2026 — Federal Funding Opportunities

Federal funding for cancer research, clinical trials, and oncology programs from NIH, NCI, and DOD. GrantMetric surfaces every active federal notice of funding opportunity (NOFO) relevant to Ohio applicants, with award ceiling, eligibility requirements, and close dates visible at a glance.

51 active federal grants open to Ohio organizations
Eligible applicants: nonprofits, universities, state agencies, small businesses
Award floor and ceiling for each funding opportunity
Application deadlines and close dates from grants.gov — updated daily
AI-generated briefings summarizing each program's objectives

Active Grants: 51 // State: Ohio // Source: Grants.gov // Updated: Daily

Federal Grants in Ohio

Federal grants are available nationally — Ohio organizations apply directly to federal agencies. These 51 active opportunities are open to eligible applicants in Ohio right now.

Federal cancer research funding flows through the National Cancer Institute (NCI) — the world's largest single funder of cancer research — and the Department of Defense Congressionally Directed Medical Research Programs (CDMRP). Ohio research institutions compete directly in NCI's merit-based peer review system, where scientific quality determines funding outcomes regardless of geographic location. NCI-designated Cancer Centers carry particular weight in this competition, as their designation signals institutional infrastructure, research depth, and peer-reviewed scientific excellence. Research universities, academic medical centers, and independent cancer institutes in Ohio's midwest region have historically received substantial NCI funding across R01 investigator-initiated grants, U01 cooperative agreements, and P30 Cancer Center Support Grants.

For Ohio nonprofits and community organizations without internal research capacity, NCI's cancer control and prevention portfolio offers a distinct pathway. Community health education grants, patient navigation programs, tobacco cessation funding, and cancer screening outreach initiatives are specifically designed for direct service organizations serving underserved communities. State health departments, Federally Qualified Health Centers (FQHCs), patient advocacy groups, and community-based organizations in Ohio are competitive applicants for NCI community-based funding at the R03, R21, and UG1 levels. DOD CDMRP Breakthrough and Idea Awards are also accessible to both research institutions and qualified nonprofits across Ohio.

Active Opportunities for Ohio (51)

PAR-25-254 05/07/2026

Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-25-254) targets strategic development wi...

Health View Details →

PAR-25-221 01/07/2027

Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-25-221) targets strategic development wi...

Health View Details →

RFA-CA-24-026 09/28/2026

National Cancer Institute Youth Enjoy Science Research Education Program (R25 Clinical Trial Not Allowed)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: RFA-CA-24-026) targets strategic development...

Health View Details →

PAR-25-098 01/07/2027

Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-25-098) targets strategic development wi...

Health View Details →

PAR-23-284 09/25/2026

Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-23-284) targets strategic development wi...

Health View Details →

PAR-23-276 01/07/2027

Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-23-276) targets strategic development wi...

Health View Details →

PAR-23-277 01/07/2027

Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-23-277) targets strategic development wi...

Health View Details →

PAR-25-103 10/25/2027

Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-25-103) targets strategic development wi...

Health View Details →

PAR-25-145 01/07/2028

Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-25-145) targets strategic development wi...

Health View Details →

PAR-25-043 01/07/2028

Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-25-043) targets strategic development wi...

Health View Details →

PAR-25-104 10/25/2027

Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-25-104) targets strategic development wi...

Health View Details →

PAR-25-248 10/08/2027

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-25-248) targets strategic development wi...

Health View Details →

PAR-24-311 01/07/2028

Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-24-311) targets strategic development wi...

Health View Details →

PAR-25-075 10/14/2026

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-25-075) targets strategic development wi...

Health View Details →

PAR-25-175 01/07/2028

Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-25-175) targets strategic development wi...

Health View Details →

PA-25-172 01/07/2028

Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PA-25-172) targets strategic development wit...

Health View Details →

PA-25-253 09/07/2028

Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PA-25-253) targets strategic development wit...

Health View Details →

PAR-25-069 01/07/2027

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-25-069) targets strategic development wi...

Health View Details →

PAR-25-167 01/07/2027

Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-25-167) targets strategic development wi...

Health View Details →

PAR-25-081 01/07/2027

National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-25-081) targets strategic development wi...

Health View Details →

PAR-25-044 01/07/2028

Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-25-044) targets strategic development wi...

Health View Details →

PAR-25-243 01/07/2028

Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-25-243) targets strategic development wi...

Health View Details →

PAR-25-095 09/07/2026

Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-25-095) targets strategic development wi...

Health View Details →

PAR-25-070 01/07/2027

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-25-070) targets strategic development wi...

Health View Details →

PAR-25-336 11/15/2027

Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-25-336) targets strategic development wi...

Health View Details →

PAR-25-299 01/07/2028

Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-25-299) targets strategic development wi...

Health View Details →

PAR-23-278 01/07/2027

Cancer Research Education Grants Program - Curriculum or Methods Development (R25 Clinical Trial Not Allowed)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-23-278) targets strategic development wi...

Health View Details →

PAR-25-074 10/14/2026

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-25-074) targets strategic development wi...

Health View Details →

PAR-25-096 09/07/2026

Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-25-096) targets strategic development wi...

Health View Details →

PAR-25-244 11/16/2027

Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-25-244) targets strategic development wi...

Health View Details →

PAR-25-444 09/25/2028

Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-25-444) targets strategic development wi...

Health View Details →

PAR-27-073 07/05/2029

Research Opportunities in Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)

Agency HHS-NIH11

High-priority technical directive issued by HHS-NIH11. This initiative (ID: PAR-27-073) targets strategic development wi...

Health View Details →

HT942526OCRPIIRA 10/01/2026

DoW, Ovarian Cancer, Investigator-Initiated Research Award

Agency DOD-AMRAA

High-priority technical directive issued by DOD-AMRAA. This initiative (ID: HT942526OCRPIIRA) targets strategic developm...

Defense View Details →

HT942526OCRPCTA 10/01/2026

DoW Ovarian Cancer, Clinical Trial Award

Agency DOD-AMRAA

High-priority technical directive issued by DOD-AMRAA. This initiative (ID: HT942526OCRPCTA) targets strategic developme...

Defense View Details →

HT942526PCARPIDA 10/07/2026

DoW Pancreatic Cancer Research Program, Idea Development Award

Agency DOD-AMRAA

High-priority technical directive issued by DOD-AMRAA. This initiative (ID: HT942526PCARPIDA) targets strategic developm...

Defense View Details →

HT942526PCARPFPTA 10/07/2026

DoW Pancreatic Cancer Research Program, Focused Pilot Award

Agency DOD-AMRAA

High-priority technical directive issued by DOD-AMRAA. This initiative (ID: HT942526PCARPFPTA) targets strategic develop...

Defense View Details →

HT942526OCRPOCAECI 10/01/2026

DoW, Ovarian Cancer, Ovarian Cancer Academy – Early-Career Investigator Award

Agency DOD-AMRAA

High-priority technical directive issued by DOD-AMRAA. This initiative (ID: HT942526OCRPOCAECI) targets strategic develo...

Defense View Details →

HT942526BCRPBTA12 07/08/2026

DoW Breast Cancer, Breakthrough Award Levels 1 and 2

Agency DOD-AMRAA

High-priority technical directive issued by DOD-AMRAA. This initiative (ID: HT942526BCRPBTA12) targets strategic develop...

Defense View Details →

HT942526BCRPCREA 07/08/2026

DoW Breast Cancer, Clinical Research Extension Award

Agency DOD-AMRAA

High-priority technical directive issued by DOD-AMRAA. This initiative (ID: HT942526BCRPCREA) targets strategic developm...

Defense View Details →

HT942526BCRPTBCCDA 07/08/2026

DoW Breast Cancer, Transformative Breast Cancer Consortium Development Award

Agency DOD-AMRAA

High-priority technical directive issued by DOD-AMRAA. This initiative (ID: HT942526BCRPTBCCDA) targets strategic develo...

Defense View Details →

HT942526LCRPIDA 09/02/2026

DoW Lung Cancer Idea Development Award

Agency DOD-AMRAA

High-priority technical directive issued by DOD-AMRAA. This initiative (ID: HT942526LCRPIDA) targets strategic developme...

Defense View Details →

HT942526BCRPEOHS 07/08/2026

DoW Breast Cancer, Era of Hope Scholar Award

Agency DOD-AMRAA

High-priority technical directive issued by DOD-AMRAA. This initiative (ID: HT942526BCRPEOHS) targets strategic developm...

Defense View Details →

HT942526BCRPTBCCA 09/30/2026

DoW Breast Cancer, Transformative Breast Cancer Consortium Award

Agency DOD-AMRAA

High-priority technical directive issued by DOD-AMRAA. This initiative (ID: HT942526BCRPTBCCA) targets strategic develop...

Defense View Details →

HT942526LCRPTRA 09/02/2026

Lung Cancer Translational Research Award

Agency DOD-AMRAA

High-priority technical directive issued by DOD-AMRAA. This initiative (ID: HT942526LCRPTRA) targets strategic developme...

Defense View Details →

HT942526BCRPBTA4 09/30/2026

DoW Breast Cancer, Breakthrough Award Level 4

Agency DOD-AMRAA

High-priority technical directive issued by DOD-AMRAA. This initiative (ID: HT942526BCRPBTA4) targets strategic developm...

Defense View Details →

HT942526PCARPTRPA 10/07/2026

DoW Pancreatic Cancer Research Program, Translational Research Partnership Award

Agency DOD-AMRAA

High-priority technical directive issued by DOD-AMRAA. This initiative (ID: HT942526PCARPTRPA) targets strategic develop...

Defense View Details →

HT942526OCRPPA 10/01/2026

DoW, Ovarian Cancer, Pilot Award

Agency DOD-AMRAA

High-priority technical directive issued by DOD-AMRAA. This initiative (ID: HT942526OCRPPA) targets strategic developmen...

Defense View Details →

HT942526OCRPOCCTAECI 10/01/2026

DoW, Ovarian Cancer, Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award

Agency DOD-AMRAA

High-priority technical directive issued by DOD-AMRAA. This initiative (ID: HT942526OCRPOCCTAECI) targets strategic deve...

Defense View Details →

RFA-FD-26-004 06/15/2026

Novel Approaches to Support Therapeutic Development in Ultra-Rare Cancers

High-priority technical directive issued by HHS-FDA. This initiative (ID: RFA-FD-26-004) targets strategic development w...

Health View Details →

HT942526BCRPBTA3 09/30/2026

DoW Breast Cancer, Breakthrough Award Level 3

Agency DOD-AMRAA

High-priority technical directive issued by DOD-AMRAA. This initiative (ID: HT942526BCRPBTA3) targets strategic developm...

Defense View Details →

HT942526LCRPPCOSA 09/02/2026

Lung Cancer Patient-Centered Outcomes and Survivorship Award

Agency DOD-AMRAA

High-priority technical directive issued by DOD-AMRAA. This initiative (ID: HT942526LCRPPCOSA) targets strategic develop...

Defense View Details →

Frequently Asked Questions

Who funds cancer research grants in Ohio?

The National Cancer Institute (NCI) and Department of Defense (DOD) are the primary federal funders of cancer research. Ohio universities, hospitals, and research institutions are eligible to apply directly to these federal programs.

Can Ohio nonprofits apply for cancer grants?

Yes. Nonprofit research institutions, academic medical centers, and cancer-focused nonprofits in Ohio are all eligible for NCI and DOD cancer grants. Community organizations can apply for cancer prevention grants through NCI's cancer control portfolio.

More Grant Topics in Ohio

🏢 SBIR & Small Business Grants 💬 Mental Health Grants ⚡ Climate & Clean Energy Grants 🤖 AI & Technology Grants 🏥 Public Health Grants 🧬 Biomedical Research Grants 🌾 Rural & Agriculture Grants 🎓 Education & Workforce Grants 🏘️ Housing & Community Grants

Browse More

All Ohio Topics → All States → National Cancer Research Grants → Intelligence Feed →

GrantMetric Intelligence Systems — Independent federal grant intelligence platform. Not affiliated with Grants.gov, the U.S. Department of Health & Human Services, or any government agency. Grant data is sourced from the Grants.gov API for informational purposes only; always verify opportunity details directly with the funding agency before applying. Some links on this site are affiliate links — we may earn a commission at no additional cost to you. Full Disclaimer · Last Reviewed: May 2026 · Data Methodology